84 related articles for article (PubMed ID: 24218274)
1. Functional analysis of CD59 using complement-dependent cytotoxicity assay.
Kolev M
Methods Mol Biol; 2014; 1100():347-53. PubMed ID: 24218274
[TBL] [Abstract][Full Text] [Related]
2. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
3. Detection of CD59 using flow cytometry.
Kolev M
Methods Mol Biol; 2014; 1100():341-6. PubMed ID: 24218273
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59.
Qu Z; Liang X; Liu Y; Du J; Liu S; Sun W
Mol Immunol; 2009 Dec; 47(2-3):283-9. PubMed ID: 19804910
[TBL] [Abstract][Full Text] [Related]
5. Congenital CD59 Deficiency.
Höchsmann B; Schrezenmeier H
Hematol Oncol Clin North Am; 2015 Jun; 29(3):495-507. PubMed ID: 26043388
[TBL] [Abstract][Full Text] [Related]
6. Protection of MLV vector particles from human complement.
Breun S; Salmons B; Günzburg WH; Baumann JG
Biochem Biophys Res Commun; 1999 Oct; 264(1):1-5. PubMed ID: 10527830
[TBL] [Abstract][Full Text] [Related]
7. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
[TBL] [Abstract][Full Text] [Related]
8. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
[TBL] [Abstract][Full Text] [Related]
10. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.
Gancz D; Fishelson Z
Mol Immunol; 2009 Sep; 46(14):2794-800. PubMed ID: 19501402
[TBL] [Abstract][Full Text] [Related]
11. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.
Babiker AA; Nilsson B; Ronquist G; Carlsson L; Ekdahl KN
Prostate; 2005 Feb; 62(2):105-14. PubMed ID: 15389819
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
Brasoveanu LI; Fonsatti E; Visintin A; Pavlovic M; Cattarossi I; Colizzi F; Gasparollo A; Coral S; Horejsi V; Altomonte M; Maio M
J Clin Invest; 1997 Sep; 100(5):1248-55. PubMed ID: 9276743
[TBL] [Abstract][Full Text] [Related]
13. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
14. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
15. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
Brooimans RA; van Wieringen PA; van Es LA; Daha MR
Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
17. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer.
Imai M; Landen C; Ohta R; Cheung NK; Tomlinson S
Cancer Res; 2005 Nov; 65(22):10562-8. PubMed ID: 16288049
[TBL] [Abstract][Full Text] [Related]
19. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
20. Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59.
Yin Z; Wang L; Xiang Y; Ruan Y; Li J; Wang X; Ichim TE; Chen S; Chen G
Xenotransplantation; 2010; 17(3):215-23. PubMed ID: 20636542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
